The announcement of high sensitivity and specificity for the Oncoguard Esophagus Test is significant for Exact Sciences. Positive data from medical tests often lead to increased investor confidence, potentially driving up the stock price. Given the test's focus on esophageal cancer, a critical and underserved medical area, this development could significantly impact the company's product portfolio and future earnings.